Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy

F. Malek, P. Krueger, Z. N. Hatmi, A. A. Malayeri, H. Faezipour, R. J. O'Donnell

Research output: Contribution to journalArticlepeer-review

54 Scopus citations


Giant cell tumour (GCT) is a benign, but aggressive, primary tumour of the bone. The recurrence rate after surgical treatment has been reported to be as high as 50%. Many surgical techniques have been employed in the treatment of this tumour. More aggressive interventions, such as en bloc resection and bulk allograft or prosthetic reconstruction, are generally understood to be associated with lower rates of local recurrence. However, because of lessened morbidity, intralesional techniques have come to be favoured for this condition. In addition to curettage, various adjuvant procedures and packing materials have been advocated in order to control and reconstruct long bone defects secondary to this neoplasm. We report our experience with 40 long bone GCT patients treated with curettage, burring, bone grafting and no adjuvants between 1997 and 2002. There was a local recurrence rate of 32.5%, with most recurrences noted within the first 30 months after surgery. Minor complications were found in 18% of patients. The risk of local recurrence in this study is acceptable (within the range that has been historically reported for curettage and bone grafting). In cases where more resources are available, the addition of adjuvant therapies, as noted in the recent literature, may be beneficial. The results of this study should be considered when designing multicenteric studies in the future.

Original languageEnglish (US)
Pages (from-to)495-498
Number of pages4
JournalInternational Orthopaedics
Issue number6
StatePublished - Dec 2006
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine


Dive into the research topics of 'Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy'. Together they form a unique fingerprint.

Cite this